SCHEMBL4521816

SCHEMBL4521816

OCC#Cc1ccc(Br)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 1/20 0.37
ADRA2A P08913 2/20 0.35
ADRA2B P18089 2/20 0.35
ADRA2C P18825 2/20 0.35
PLAU P00749 1/20 0.35
GBA1 P04062 1/20 0.35
MELK Q14680 1/20 0.33
TSHR P16473 1/20 0.33
MCHR1 Q99705 1/20 0.32
HTT P42858 2/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
RECQL P46063 1/20 0.32
RAB9A P51151 2/20 0.32
NPC1 O15118 2/20 0.32
PKM P14618 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
GAA P10253 1/20 0.32
GRM5 P41594 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4764093 0.85 KDM4E (0.35) ALDH1A1KDM4EADRA2AADRA2BADRA2C
SCHEMBL4764055 0.81 GBA1 (0.43) ALDH1A1KDM4EADRA2AADRA2BADRA2C
SCHEMBL4504786 0.77 GRM5 (0.35) ALDH1A1KDM4ETSHRGRM5FFAR1
SCHEMBL1535553 0.77 GRM5 (0.50) ALDH1A1ADRA2AADRA2BADRA2CPLAU
SCHEMBL31044575 0.77 GRM5 (0.46) ALDH1A1MELKHTTGAAGRM5
SCHEMBL22031550 0.77 GRM5 (0.46) ALDH1A1MELKHTTGAAGRM5
SCHEMBL29756638 0.77 GRM5 (0.43) ALDH1A1KDM4EGBA1MCHR1RAB9A
SCHEMBL285550 0.77 GRM5 (0.43) ALDH1A1KDM4EGBA1MCHR1RAB9A
SCHEMBL6041898 0.77 GBA1 (0.38) ALDH1A1KDM4EGBA1RAB9ANPC1
SCHEMBL20120587 0.76 APP (0.35) MCHR1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112189010-B Triazole N-linked carbamoyl cyclohexyl acid as LPA antagonists 百时美施贵宝公司 2026-05-15 CN disclosed
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2025-10-02 US disclosed
US-20250057815-A1 CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-02-20 US disclosed
US-12195444-B2 Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists BRISTOL-MYERS SQUIBB COMPANY (US) 2025-01-14 US disclosed
US-20240425517-A1 NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION PRAZER THERAPEUTICS INC. (KR) 2024-12-26 US disclosed
EP-4450490-A1 NOVEL COMPOUND FOR DEGRADING TARGET PROTEIN OR POLYPEPTIDE BY USING POLYUBIQUITINATION Prazer Therapeutics Inc. (KR) 2024-10-23 EP disclosed
CN-118382620-A Novel compounds for degrading target proteins or polypeptides by multiple ubiquitination 普瑞泽治疗公司 2024-07-23 CN disclosed
US-11999717-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-06-04 US disclosed
CN-114728168-B Triazole carbamate pyridylsulfonamides as LPA receptor antagonists and their use 吉利德科学公司 2024-04-09 CN disclosed
US-11912686-B2 LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-27 US disclosed
US-20130123249-A1 NOVEL BENZOXAZINE OXAZOLIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF NANJING CHANGAO PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LIMITED (CN) 2013-05-16 US disclosed
EP-2578591-A1 NOVEL BENZOXAZINE OXAZOLIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF Shanghai Institute Materia Medica, Chinese Academy Of Sciences (CN) 2013-04-10 EP disclosed
CN-102260277-A Novel benzoxazine oxazolidinone compound and preparation method and application thereof 2011-11-30 CN disclosed
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2010-01-28 US disclosed
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-03-12 US disclosed
US-7452911-B2 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2008-11-18 US disclosed
US-20050245529-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 US disclosed
US-20050239826-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-27 US disclosed
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-10-21 US disclosed
US-4937251-A TREATING ASTHMA AND BRONCHITIS; ADRENERGIC STIMULANTS GLAXO GROUP LIMITED (GB) 1990-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022515-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GCGR, GPR65 ALDH1A1 2253/4885KDM4E 2943/4885ADRA2A 125/4885
US-20240425517-A1 NOVEL COMPOUND FOR DEGRADATION OF TARGET PROTEIN OR POLYPEPTIDE BY POLYUBIQUITINATION ADRM1, SUMO1, SUMO2 ALDH1A1 3989/4885KDM4E 2717/4885ADRA2A 4011/4885
US-20130123249-A1 NOVEL BENZOXAZINE OXAZOLIDINONE COMPOUNDS, PREPARATION METHODS AND USES THEREOF XDH, OXA1L, CYP3A5 ALDH1A1 740/4885KDM4E 2762/4885ADRA2A 2383/4885
US-20090069282-A1 ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS MCHR1, MCHR2, GPR119 ALDH1A1 3188/4885KDM4E 1349/4885ADRA2A 96/4885
US-20050239826-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, MCHR2, GPR119 ALDH1A1 1855/4885KDM4E 1398/4885ADRA2A 78/4885
US-20040209865-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, MCHR2, NPY1R ALDH1A1 2991/4885KDM4E 1450/4885ADRA2A 76/4885
US-11999717-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof LPAR3, LPAR1, LPAR2 ALDH1A1 2326/4885KDM4E 2137/4885ADRA2A 2363/4885
US-20250057815-A1 CARBAMOYLOXYMETHYL TRIAZOLE CYCLOHEXYL ACIDS AS LPA ANTAGONISTS LPAR3, LPAR1, LPAR2 ALDH1A1 3382/4885KDM4E 2834/4885ADRA2A 467/4885
US-12195444-B2 Triazole n-linked carbamoyl cyclohexyl acids as LPA antagonists LPAR3, LPAR1, LPAR2 ALDH1A1 3478/4885KDM4E 3031/4885ADRA2A 775/4885
US-20050245529-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 ALDH1A1 3033/4885KDM4E 1952/4885ADRA2A 75/4885
US-20250304554-A1 LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR4 ALDH1A1 1726/4885KDM4E 2095/4885ADRA2A 806/4885
US-11912686-B2 LPA receptor antagonists and uses thereof LPAR1, LPAR2, LPAR4 ALDH1A1 1726/4885KDM4E 2095/4885ADRA2A 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.